Novartis Pharma AG 13D and 13G filings for GAMIDA CELL LTD:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-26 4:17 pm Unchanged | 2023-05-10 | 13D | GAMIDA CELL LTD GMDAQ | Novartis Pharma AG | 4,336,759 4.100% | 0 (Unchanged) | Filing |
| 2023-03-03 4:02 pm Sale | 2022-12-30 | 13D | GAMIDA CELL LTD GMDAQ | Novartis Pharma AG | 4,336,759 5.800% | -857,295 (-16.51%) | Filing |
| 2021-03-11 4:35 pm Unchanged | 2021-03-01 | 13D | GAMIDA CELL LTD GMDAQ | Novartis Pharma AG | 5,194,054 8.800% | 0 (Unchanged) | Filing |
| 2020-08-14 4:49 pm Purchase | 2019-06-28 | 13D | GAMIDA CELL LTD GMDAQ | Novartis Pharma AG | 5,194,054 10.300% | 1,919 (+0.04%) | Filing |